Hennion & Walsh Asset Management Inc. Sells 82,233 Shares of Celcuity, Inc. $CELC

Hennion & Walsh Asset Management Inc. lowered its holdings in shares of Celcuity, Inc. (NASDAQ:CELC) by 45.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 100,368 shares of the company’s stock after selling 82,233 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Celcuity were worth $10,500,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. NEA Management Company LLC grew its position in Celcuity by 64.9% during the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after buying an additional 1,391,300 shares during the period. Avoro Capital Advisors LLC bought a new position in Celcuity in the fourth quarter worth approximately $310,302,000. Soleus Capital Management L.P. raised its position in Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares during the period. Vanguard Group Inc. boosted its stake in shares of Celcuity by 10.7% during the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after acquiring an additional 220,386 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after acquiring an additional 914,887 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $92.79 on Friday. The company has a market capitalization of $4.53 billion, a P/E ratio of -23.79 and a beta of 0.20. Celcuity, Inc. has a 1-year low of $44.16 and a 1-year high of $151.02. The firm’s 50 day simple moving average is $94.57 and its two-hundred day simple moving average is $109.08. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. Research analysts expect that Celcuity, Inc. will post -3.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CELC has been the subject of a number of recent research reports. Leerink Partners set a $155.00 price objective on shares of Celcuity in a research report on Tuesday, June 2nd. Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a report on Wednesday, July 15th. Needham & Company LLC reiterated a “buy” rating and set a $157.00 target price on shares of Celcuity in a research report on Friday, May 15th. Stifel Nicolaus set a $150.00 price target on Celcuity in a report on Monday, May 4th. Finally, Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and an average price target of $155.18.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.